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Nacystelyn (NAL), a recently-developed lysine salt of N-acetylcysteine (NAC), and NAG, both known 
to have excellent mucolytic capabilities, were tested for their ability to enhance cellular antioxidant 
defence mechanisms. To accomplish this, both drugs were tested in vitro for their capacity: (1) to inhibit 
0, - and H20, in cell-free assay systems; (2) to reduce 0, - and H,O, released by polymorphonuclear 
leukocytes (PMN); and (3) for their cellular glutathione (GSH) precursor effect. 
In comparison with GSH, NAL and NAC inhibited H,O,, but not 0, -, in cell-free, in vitro test 
systems in a similar manner. The anti-H,O, effect of these drugs was as potent as that of GSH, an 
important antioxidant in mammalian cells. To enhance cellular GSH levels, increasing concentrations 
(O-2 x 10 - 4 mol 1 - ‘) of both substances were added to a transformed alveolar cell line (A549 cells). 
After NAC administration (2 x 10 -’ mol 1 - ‘), total intracellular GSH (GSH+2GSSG) levels reached 
4.5 f 1.1 x 10 - 6 mol per lo6 cells, whereas NAL increased GSH to 8.3 f 1.6 x 10 - 6 mol per lo6 cells. 
NAC and NAL administration also induced extracellular GSH secretion; about two-fold (NAC), and 
1.5fold (NAL), respectively. The GSH precursor potency of cystine was about two-fold higher than that 
of NAL and NAC, indicating that the deacetylation process of NAL and NAC slows the ability of both 
drugs to induce cellular glut production and secretion. Buthionine-sulphoximine, which is an inhibitor 
of GSH synthetase, blocked the cellular GSH precursor effect of all substances. In addition, these data 
demonstrate that NAC and NAL reduce H,O, released by freshly-isolated cultured blood PMN from 
smokers with chronic obstructive pulmonary disease (COPD) (n= 10) in a similar manner (about 45% 
reduction of H,O, activity by NAC or NAL at 4 x 10 -’ mol l- ‘). In accordance with the results 
obtained from cell-free, in vitro assays, O,- released by PMN was not affected. Ambroxol (concen- 
trations: 10 - 9-1 0 - 3 mol 1 - ‘) d’d 1 not reduce activity levels of H20, and O,- in vitro. Due to the basic 
effect of dissolved lysine, which separates easily in solution from NAL, the acidic function of the 
remaining NAC molecule is almost completely neutralized [at concentration 2 x 10 - 4 M: pH 3.6 (NAC), 
pH 6.4 (NAL)]. 
Due to their function as H,O, scavengers, and due to their ability to enhance cellular glutathione 
levels, NAL and NAC both have potent antioxidant capabilities in vitro. The advantage of NAL over 
NAC is two-fold; it enhances intracellular GSH levels twice as effectively, and it forms neutral pH 
solutions whereas NAC is acidic. Concluding from these in vitro results, NAL could be an interesting 
alternative to enhance the antioxidant capacity at the epithelial surface of the lung by aerosol 
administration. 
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Introduction 
A variety of acute and chronic inflammatory 
diseases of lung and airways are characterized 
by an excess of highly-reactive oxygen species 
(1). In many of these disorders, such as cystic 
fibrosis, idiopathic pulmonary fibrosis, asbes- 
tosis and adult respiratory distress syndrome 
(ARDS), the epithelial surface is exposed to an 
intense burden of oxidants derived from large 
numbers of activated macrophages and poly- 
morphonuclear leukocytes (PMN) (1,4). Fur- 
thermore, pulmonary diseases (e.g. cancer and 
emphysema) associated with cigarette smoke, 
which contains high concentrations of free 
radicals or chemicals that readily react to form 
free radicals, are, at least in part, mediated by 
oxidants (5). Although bronchoepithelial cells 
contain high levels of antioxidants to contend 
with such oxidants, when the inflammation is 
overwhelming, the antioxidant screen may 
become inadequate, resulting in oxidant- 
mediated epithelial injury (6,7). Radical-induced 
injury is characterized among others by DNA 
strand breaks, induction of lipid peroxidation 
and inactivation of proteins (e.g. al-anti-trypsin) 
(8). In the past, various approaches to augment 
the antioxidant screen of the epithelial surface 
have been made in order to make epithelial 
cells more resistant to the external and internal 
oxidant burden (9,lO). Glutathione (GSH) and 
GSH redox cycle enzymes, one of the most 
important antioxidant defence mechanisms in 
mammalian cells, also have an important role in 
the detoxification process of various exogenous 
compounds (e.g. paracetamol, metals, alkylating 
agents) (11,12). In the context of these consid- 
erations, a rational therapy in these disorders is 
to augment GSH levels in the lung (9,13). Vari- 
ous attempts have been made to enhance 
the GSH screen on the epithelial surface of the 
lung utilizing L-2-oxothiazolidine-4-carboxylate 
(activator of GSH synthesis) (14), thiozolidin 
(intracellular cysteine precursor) (14,15), 
y-glutamylcystine or y-glutamylcysteine (sub- 
strates of GSH synthetase), cysteine, cystinyl-bis- 
glycine, glutamate (substrates of y-glutamyl 
cycle) (15), or GSH monoester (GSH derivative) 
(16). However, none of these approaches have 
demonstrated clinical importance. Due to rapid 
auto-oxidation in viva, but possibly also due 
to its short half-life, most applications of aero- 
solized GSH have resulted in elevated GSH 
levels in the epithelial lining fluid for less than 
2 h (9). To overcome this problem, attempts with 
liposome-encapsulated GSH have been made 
(17). Administration of compounds with GSH 
precursor function resulted in a long-lasting 
GSH augmentation (days) of intracellular GSH 
levels (4,18,19). In this context, N-acetylcysteine 
(N-acetyl-L-cysteine; NAC), a compound devel- 
oped in the 1960s which is the N-acetyl- 
derivative of L-cysteine, not only reduces 
disulphide bonds but also has the potential to 
interact directly with oxidants. In addition, it has 
cellular GSH precursor function, and seems to 
be a promising approach for the enhancement of 
antioxidant defence in the lung (20). Nacystelyn 
(NAL), a recently developed lysine salt of NAC, 
seems also to have potent mucolytic capabilities, 
and has the marked advantage over NAC of 
being easily aerosolized into the lung without 
causing significant side-effects (21,24). NAC is 
acidic in solution, and inhalation may be associ- 
ated with coughing or induction of asthma 
attacks (25). Thus, NAL may represent an inter- 
esting alternative approach to augmenting the 
antioxidant screen in the lung. This, however, 
has not yet been evaluated. 
Based on the knowledge that thiols, like NAC, 
have good antioxidant function, the purpose 
of the present study was to compare the anti- 
oxidant capabilities of NAL with NAC in order 
to define the feasibility of using NAL in anti- 
oxidant therapy. To accomplish this, both drugs 
were investigated in vitro: (1) to inhibit hydrogen 
peroxide (H202) and superoxide anion (0, -), 
and (2) to induce cellular GSH synthesis and 
release. 
Materials and Methods 
MATERIALS 
A549 cells were obtained from ATCC (American 
Type Cultured Collection, Bethesda, MD, 
U.S.A.). The cells were cultured in 24-well cul- 
ture plates (Corning, NY, U.S.A.) in Dulbecco’s 
modified Eagle’s medium (DMEM; Sigma 
Chemical Co., Deisenhofen, Germany) with 
10% fetal calf serum (FCS Gibco, Eggenstein, 
Germany) with or without cystine or cysteine at 
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37”C/5% CO,, in 100% humidity. PMN were 
cultured in 96-well plates (Falcon, Lincoln Park, 
NJ, U.S.A.). Hanks’ balanced salt solution 
(HBSS), which was used in the H,O, and 0, - 
assays (as basic buffer as well as for rinsing), was 
acquired from Gibco (Eggenstein, Germany). 
Percoll@ came from Pharmacia (Freiburg, 
Germany). Ferricytochrome c, phenolsulphon- 
phthalein (phenol red), horseradish peroxidase 
(type VI), EDTA (disodium salt), reduced 
/?-nicotinamide adenine dinucleotide phos- 
phate (NADPH), xanthine, xanthine oxidase, 
superoxide dismutase (SOD) from human 
erythrocytes, cystine, reduced GSH, GSH 
reductase, GSH peroxidase, D/L-buthionine- 
[S-RI-sulphoximine (BSO), 5,5’-dithiobis(2- 
nitrobenzoic acid) (DTNB) and phorbol 
12-myristate 13-acetate (PMA) were from 
Sigma Chemical Co. (Deisenhofen, Germany). 
Ambroxol-hydrochloride was acquired from 
Aldrich (Steinheim, Germany). Hydrogen perox- 
ide (H,O*), triton X-100 and trypan blue were 
obtained from E. Merck (Darmstadt, Germany). 
N-acetylcysteine was kindly provided by Klinge 
Pharma (Munich, Germany). Nacystelyn was 
provided by Laboratoires SMB & Galephar 
(Brussels, Belgium). 
STUDY DESIGN 
To examine the antioxidant capacity of NAL 
and NAC, the products were tested in vitro to 
inhibit 0, - and H,O, in cell-free assay systems. 
GSH precursor function was examined as stimu- 
lation of GSH synthesis in cultured A549 cells. 
Finally, extracellular administration of NAC 
and NAL were investigated for reduction of 
O,- and H,O, p reduced by cultured PMN. As 
intravenous administration of NAC (600 mg i.v., 
single dose, normal volunteers) in man peaks in 
mean plasma levels of about 2 x 10 - 4 mol 1 - ‘, 
NAC in cell-dependent assay systems not 
exceeding that concentration were tested (26). 
The 0, -, H,O, and GSH assays were done in 
duplicates in four different trials. Trypan blue 
analysis confirmed in all cell-dependent assays 
that cell viability remained always >95% (with 
and without the drugs tested). Figure 1 demon- 
strates the chemical structure of NAL and 
NAC. The data of all assays are represented as 
arithmetic mean values f SD. 
(a) 
SH- CH,- CH-COOH 
NH-C-CH, 
II 
0 
(b) 
SH-CH,-CH-COOH x H,N-(CH,),-CH-COOH 
NH-C - CH, 
II 
NH, 
0 
(cl 
2(R-SH)+H,O, d R-S-S-R+2H,O 
FIG. 1. Molecular structure of N-acetylcysteine 
(NAC) (a) and Nacystelyn (NAL) (b). SH-groups of 
both thiols can be oxidized by H,O, and thus 
reduce H,O, to H,O (R=acetyl residue). 
DETERMINATION OF GSH 
Total GSH (GSH+2GSSG) in cells and cell 
medium was determined according to a method 
described previously (27). The GSH reductase- 
DTNB recycling assay of GSH utilizes the 
specificity of GSH reductase and the sensitivity 
of DTNB. The reaction was spectrophotometri- 
tally monitored at 412 nm (27). The concen- 
tration of total GSH was calculated by 
comparing the reduction rate of the samples with 
standard curves of known concentrations 
(GSSG: 2.5 x 10W7-8 x 10W6 mall-‘). 
o,- ASSAY 
The O2 - assay consisted of an 0, - generating 
system and an O2 - detection system. 0, - 
was generated in HBSS containing Na,EDTA 
(10e4 mall-‘), xanthine (5 x 10W5 mall-‘) 
and xanthine oxidase (69.5 PU per 3 ml). The 
detection of 0, - generation is based on the 
proportional SOD-inhibitable reduction of ferri- 
cytochrome c (8 x 10 - 5 mol l- ‘), which was 
monitored at 550 nm, as described .previously 
(10). To avoid interference of thiols with ferri- 
cytochrome c, pH was adjusted to 7.4 (28). 0, - 
was quantified as a rate of uninhibited vs. SOD- 
inhibited (10 - 3 mol 1 - ‘) reduction of ferri- 
cytochrome c (3,10,29). No O2 - activity was 
assumed at 10 - 3 mol l- ’ SOD, whereas the 
0, - generating system by itself (no inhibition) 
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was referred to as 100% 0, - activity. Possible 
interaction of the substances tested with the 
assay system (ferricythochrome c-xanthine- 
xanthine oxidase) was excluded. To inhibit 0, - 
NAC and NAL were added to the O2 - assay in 
concentrations ranging 10 - 5-10 - 3 mol 1 - ‘. 
Equimolar amounts of SOD were used as a 
positive control. Ambroxol and cystine were the 
negative controls. 
H,O, ASSAY IN VlTRO 
Due to interference of thiols with horseradish- 
peroxidase-based H,O, detection systems as 
described in Yamada et al. (1991), a slight 
modification of the DTNB, GSH and GSH- 
peroxidase-dependent assay was used (30). 
Briefly, H,O, standard (2 x 10 - 4 mol l- ’ H,O, 
per lo-* mall-’ KPO, buffer, pH 7.4) was 
incubated (5 min/37”C) with GSH (10 - 3 
mol l- ‘) and GSH-peroxidase (1 U ml - ‘). Tris- 
HCl buffer (2 x 10 - ’ mol l- ‘, pH 8.5, DTNB 
10W3 mall-‘) was added (1: 10) and change in 
optical density was monitored at 412 nm. To test 
anti-H,O, capabilities, NAC and NAL (0 and 
1O-g-1O-3 mall-‘) were added to the DTNB- 
GSH-GSH-peroxidase assay (incubation 1 h 
with 2 x 10 - 4 mol l- i H,O,). The test system 
without H,O, (2 x 10 - 4 mol 1 - ’ H202= 100% 
H,O, activity) was designated as 0% H,O, 
activity. Equimolar amounts of ambroxol were 
used as a negative control, GSH was the positive 
control. 
CELLULAR GSH PRECURSOR FUNCTION 
To examine GSH precursor function, A549-cells, 
a cell line derived from adenocarcinoma with 
pneumocyte type II characteristics, were grown 
in 24-well plates (1 ml well - ‘, DMEM/ 
lO%FCS) to 75% confluence. After an additional 
incubation period (24 h) in cysteine and cystine- 
free DMEM, the cells were washed in HBSS 
(3 x ), and NAL or NAC were added in concen- 
trations ranging from 0, 2 X 10 - 5, 4 X 10 - 5, 
10m4-2 x 10m4 mall-‘. After 1, 4, 7 and 24 h, 
total GSH was determined extracellularly in 
medium and intracellularly in lysed cells (3% 
Triton X-lOO/HBSS). The concentration of total 
GSH was expressed as 10 - 6 mol per lo6 cells. 
Equimolar amounts of cystine (cys-cys) were 
TABLE 1. Anthropomorphic data and lung function 
analysis of patients 
Parameters 
PMN isolation 
smokers (n = 10) 
Age (mean years) 
Sex (male/female) 
Smoker (pack years) 
Daily cigarette consumption 
(min-max) 
Non-smokers (n) 
Lung function tests 
FEVi (%pred.) 
FEV,/%VC 
FEF,, (%pred.) 
VC (%pred.) 
Raw (cm H,O 1 - ‘s - ‘) 
IGV (%pred.) 
61 f7 
812 
23 f 12 
lo-50 
0 
56.7 f 38.9 
63-O f 31.5 
41.5 f 34.7 
67.3 zk 10.9 ,;, 
5.1 5 3.5 
129.6 f 32.0 
Lung function parameters (48): VC (vital capacity), 
FEV, (forced expiratory volume in 1 s), FEV,/%VC 
(FEV, % of VC), FEF,, (forced expiratory flow at 
50% VC), R,, (airway resistance), IGV (intra- 
thoracic gas volume). 
used as positive control. BSO (4 x 10 - 5 
mol 1 - ‘), an inhibitor of GSH synthetase, was 
taken as negative control. 
NAC AND NAL INHIBIT 0, - FROM PMN 
Polymorphonuclear leukocytes were obtained 
from 10 smokers with chronic obstructive lung 
disease (COPD) (Table l), and were isolated 
using a one-step purification procedure with a 
discontinuous gradient of Percoll (31). Cultured 
PMN from smokers are known to be highly 
activated, and thus produce high amounts of 
oxygen radicals. Therefore, cultured PMN are 
quite suitable for testing antioxidant capabilities 
(= inhibition of 0, - , produced by PMN) of 
NAC, NAL and GSH (32,33). 
For determination of cellular 0, - produc- 
tion, 50 000 cells well - ’ were first incubated in 
96-well plates in DMEM, with or without NAC, 
NAL and GSH (concentrations ranging from 0 
to 10 - 4 mol 1 - ‘). After washing the cells three 
times in HBSS, cell medium was changed to 
HBSS/2 x 10 - 8 mol 1 - ’ PMA/ferricytochrome 
c (8 x 10 - 5 mol 1 - ‘)/pH 7.4, with or without 
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SOD (see above). After an incubation period of 
1 h (37”C, 5% CO,), the supernatant was centri- 
fuged to extricate cells and cell debris. Reduction 
of ferricytochrome c was measured in an ELISA- 
reader (Dynatech MR 500, Chantilly, VA, 
U.S.A.) at 550 nm. One hundred percent 0, - 
activity was taken to mean uninhibited 0, - 
(produced by PMN). 
NAL AND NAC TO INHIBIT H,O, 
PRODUCED BY PMN 
Nacystelyn, NAC and GSH were also exam- 
ined to inhibit H,O, produced by PMN. The 
assay was based on the H,O,-dependent and 
horseradish-peroxidase-mediated oxidation of 
phenol red (34,35). For that purpose, 150 000 
cells well - ’ were first incubated in 96-well plates 
in DMEM with or without NAC, NAL and 
GSH (concentrations and incubation procedure 
as above). After washing the cells three times in 
HBSS, cell medium was changed to HBSS/ 
phenol red (2.8 x 10 - 4 mol 1 - ‘)/horseradish 
peroxidase (8.5 U ml- ‘)/2 x 10 - ’ mol 1 - ’ 
PMA (1 ml well - ‘). Then the cells were again 
incubated for 1 h. Supernatants were centrifuged 
to extricate cells and cell debris. Addition of 
10~1 1 N NaOH brought the supernatant up to 
pH 12.5, and oxidation of phenol red was deter- 
mined sprectrophotometrically at 610 nm. One 
hundred percent H,O, activity meant uninhib- 
ited H,O, (produced by PMN). All measure- 
ments were done in triplicate. 
pH MEASUREMENTS 
pH measurements were performed with pH 
meter from Beckman (Model: @ pH 10; 
Beckman Instruments, Palo Alto, CA, U.S.A.). 
To quantify the influence on the pH, NAC and 
NAL were tested in dH,O (pH 7-O). 
STATISTICAL ANALYSIS 
All data are presented as arithmetic mean values 
with standard deviation. All statistical compari- 
sons were made using a one-way, repeated 
measures ANOVA test (analysis of variance). 
For multiple comparisons, the Student- 
Newman-Keuls test was conducted. P~0.05 was 
accepted as indicative of significant differences 
between the groups. 
CONSENT OF THE LOCAL ETHICS 
COMMITTEE 
Prior to all experiments, written consent to per- 
form the study with human cells was obtained 
from the local Ethics Committee of Ruhr- 
University Bochum, Germany. After being 
informed in detail, and before any examination, 
all patients had to sign an agreement stating 
free and voluntarily participation in the exper- 
imental procedures described above. All clinical 
investigations were conducted according to the 
principles of the Declaration of Helsinki. 
Results 
ANTI-I&O, CAPABILITIES 
Both NAC and NAL had significant intrinsic 
anti-H,O, capabilities in a cell-free, in vitro cell 
system (WO.05). Both substances have similar 
abilities to inhibit H,O, which is comparable 
with that of GSH (Fig. 2). At the concentration 
of10W3mo11-‘,inhibitionof2 x 10-4m011-1 
H,O, was almost 40% (NAC and NAL). In 
contrast, equimolar amounts of ambroxol (nega- 
tive control) revealed no anti-H,O, scavenging 
capacity. This assay enables the calculation of 
the first-order rate constant (K) between NAC 
or NAL with H,02. At 10 - 3 mol l- ‘, K was 
as follows: NAC (O-012 min- ‘); NAL 
(O-02 min - ‘). Thus, the rate of reaction of the 
two thiols with H,Oz is slow. 
ANTI-O, - CAPABILITIES 
0, - was not inhibited by NAC, NAL and GSH 
(Fig. 3). Also cys-cys and ambroxol were 
lacking anti-O, - effect (data not shown). In 
contrast, SOD resulted in a complete inhibition 
of o,- activity. 
GSH PRECURSOR EFFECT IN VITRO 
Stimulation of cellular GSH synthesis increased 
over time (highest total GSH levels at 24 h which 
are demonstrated in Figs 4 and 5), and was most 
evident at the highest substance concentration 
used (2 x 10 - 4 mol 1 - ‘). Increase of extracellu- 
lar total GSH in NAC-treated cells was higher 
than in cells treated with NAL (Fig. 4; 2 x 10 - 4 
mol per lo6 cells: NAC vs. NAL, P-=0*05); vice 
164 A. GILLISSEN ET AL. 
110 
T -r 
100 
8 
& so 
:E 
2 0” 80 
x” 1 
* 
70 
6OI,, , , , , , , y / 
0 1o-g loa 1o-7 1o-e lo4 lo4 1o-3 
Concentration (mol l-l) 
FIG. 2. N-acetylcysteine (w), Nacystelyn (V) 
glutathione (0, positive control) inhibit H,O, 
activity in a comparable fashion in vitro. Equimolar 
amounts of ambroxol (0, negative control) have no 
intrinsic anti-H,O, capacity. Data are expressed 
as mean values ( f standard deviation (*P<O.O5, 
comparison 0 vs. *). 
140, T I 
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FIG. 3. Neither N-acetylcysteine (D), Nacystelyn 
(D) nor reduced glutathione (0) inhibit 0, - 
in vitro. Superoxide dismutase (0) was used as a 
positive control. Data are expressed as mean 
values f standard deviation. 
versa, NAL administration resulted in higher 
intracellular total GSH production compared 
with NAC (Fig. 5; 2 x 10e4 mol per lo6 cells: 
NAC vs. NAL, WO.05). After NAC, NAL or 
cystine administration, intracellular increase of 
total GSH levels was much higher than extra- 
cellular total GSH release (Figs 4 and 5). In 
comparison, cystine stimulated GSH-synthesis 
more effectively than NAC and NAL in these 
cells (Figs 4 and 5; 2 x 10 - 4 mol per lo6 cells: 
cystine vs. NAC and NAL, WO.01). 
I I ,1/11/l I 
0 2x1o-5 3x105 lo4 2x10A 
Concentration (mol l-I) 
FIG. 4. In cultured A549 cells (incubation time: 
24 h), cystine (0, cysscys) but also N-acetylcysteine 
(m) and Nacystelyn (V) - although comparably 
less - result in an increase of extracellular gluta- 
thione (GSH + 2GSSG) increase. Co-incubation with 
BSO (0) [D/L-buthionine-(S-R)-sulphoximine] com- 
pletely suppresses cellular GSH precursor effect. 
Data are expressed as mean values f standard 
deviation (*P<O*O5, comparison 0 vs. *; *=P<O-05, 
comparison within the same concentration). 
INHIBITORY EFFECT ON OXIDANTS 
PRODUCED BY PMN 
To analyse whether NAC and NAL (positive 
control=GSH; negative control=no antioxidant 
inhibition) could also reduce oxidants produced 
ex vivo by inflammatory cells, PMN from current 
smokers suffering from COPD were isolated, cul- 
tured and activated with PMA. All three thiols 
inhibited H,Oz produced by these cells signifi- 
cantly (comparison 0 vs. 10 - 9 mol 1 - i: GSH 
PcO.05, NAC and NAL PcO.01). Higher con- 
centrations of extracellular NAC, NAL and 
GSH inhibited H,O, more effectively than lower 
concentrations (Fig. 6). Interestingly, no signifi- 
cant difference in efficacy between NAC, NAL 
and GSH was observed (Fig. 6). 
Concomitantly with the in vitro results 
described earlier, neither NAC, NAL nor 
GSH inhibited 0, - released by PMN (P>O.O5, 
Fig. 7). 
pH MEASUREMENTS 
pH measurements revealed acidic properties of 
NAC with increasing concentrations: pH 7.0 
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FIG. 5. After adding N-acetylcysteine (W), Nacyste- 
lyn (V) and cystine (0) (cys~ys) to cultured A549 
cells (incubation time: 24 h) stimulation of intra- 
cellular glutathione (GSH + 2GSSG) synthesis is as 
follows: cys-cys>NAL>NAC. Co-incubation with 
BSO (0) [D/L-buthionine-(S-R)-sulphoximine] com- 
pletely suppresses cellular GSH precursor effect. 
Interestingly, NAL and NAC increase cellular total 
GSH more than extracellular total GSH release, 
whereas NAL has twice the GSH precursor func- 
tion of NAC. Data are expressed as mean 
values & standard deviation (*P<O.O5 comparison 0 
VS. *; f=P<0.05, comparison within the same 
concentrations). 
(dH,O), pH 3.6 f O-2 (NAC: 2 x 10 - 4 mol 1 - ‘). 
In contrast, NAL only slightly decreased pH 
values: pH 6.4 f 0.4 (NAL: 2 x 10 - 4 mol 1 - ‘). 
As DMEM is a buffer, neither NAC nor NAL 
could alter the pH, which would have otherwise 
damaged the cultured cells (A549, PMN). 
Discussion 
Depletion of GSH, a tripeptide thiol, which 
plays an important role in the protection of 
diverse tissues against reactive 0, species and 
free radicals, renders endothelial cells of the lung 
more susceptible to toxic effects of reactive 0, 
species (20,36). Thiols like NAC seem to be a 
rational therapeutic approach to protect against 
toxic oxygen metabolites for various reasons: (1) 
they scavenge reactive oxygen species, (2) they 
are rapidly deacetylated and thus supply cysteine 
for cellular GSH synthesis, and (3) they 
additionally have well-known mucolytic activity 
(4,37,38). Despite these advantages, NAC 
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FIG. 6. N-acetylcysteine (W) and Nacystelyn (V) 
[GSH as positive control (0)] were tested to inhibit 
H,O, produced by freshly isolated polymorpho- 
nuclear cells (PMN) from smokers with COPD 
(n= 10). Inhibition of cellular H,Oz increases with 
higher substance concentration added to culture 
medium (incubation time: 1 h). NAL and NAC 
have similar anti-H,O,capabilities (triple measure- 
ments). Data are expressed as mean values f 
standard deviation (*P<O.O5, comparison 0 vs. *). 
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FIG. 7. N-acetylcysteine (m) and Nacystelyn (V) 
[reduced glutathione (GSH) as positive control (o)] 
has no significant inhibitory effect on O2 - pro- 
duced by freshly isolated polymorphonuclear cells 
(PMN; incubation time: 1 h) from smokers (n = 10) 
with COPD (triple measurements, mean 
values & standard deviation). 
administration in antioxidant therapy also had 
certain disadvantages. After oral and intra- 
venous administration, NAC cannot be detected 
in the BAL, although GSH levels increase in 
GSH-deficient patients (e.g. IPF) (4,18,39,40). 
Lack of further GSH increase in BAL after NAC 
administration to normal volunteers and to 
patients with COPD, who both have normal 
GSH levels, may be due to various reasons: (1) 
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increasing GSH levels in epithelial lining fluid 
(ELF) may suppress local GSH synthesis by 
feedback inhibition (41); (2) rapid clearance of 
most of the GSH and cysteine in plasma by 
cellular GSH-transferase may limit the effect of 
NAC (18,42). From that point of view, direct 
aerosolization therapy of thiols into the airways 
may be more suitable for antioxidant therapy in 
the lung. This approach would circumvent rapid 
deactivation processes, and clearance mechan- 
isms after intravenous or oral administration. 
Furthermore, intrinsic oxygen scavenger func- 
tion of NAC would directly enhance the anti- 
oxidant screen in ELF, which is particularly 
interesting in non-GSH-deficient pulmonary dis- 
eases characterized with high oxidant load (e.g. 
severe COPD). In contrast to NAC, NAL has 
interesting additional features: (1) it can easily be 
administered into the lung by aerosolization 
without causing significant side-effects, and (2) 
NAL seems to have an additional inhibitory 
effect on human neutrophil elastase activity 
in vitro (21,24). As aerosolized NAC may cause 
asthma attacks, and direct aerosolization of 
GSH has a very short half-life time (~2 h), 
NAL seems a more promising alternative in 
antioxidant aerosol therapy using thiols (9,25). 
The results of the present study are in agree- 
ment with this approach: first, NAL (micro- 
molar amounts) has a good H,O, scavenger 
function. Second, NAL promotes cellular GSH 
synthesis. Third, even high NAL concentrations 
(2X 10W4 molll’ ) lower pH only insignifi- 
cantly. However, the drawbacks are lacking 
anti-O, - capacity, and the low reaction rate of 
thiols with H,O,(second-order rate constant for 
NAC: 0.85 M - ‘s - ’ f 10%) (28). The inhibition 
ofO,-, if any, by NAC occurred with a second- 
order rate constant of less than 10 - 3 M - ‘s - ’ 
(28). Thus, anti-H,O, capacities of NAL and 
NAC may only play a significant biological role 
if these thiols are used to influence high levels of 
H,O, in the local milieu. Nevertheless, thiols are 
known to react quickly with hypochlorous acid 
(HOCL) and hydroxyl radical (*OH) as deter- 
mined by pulse radiolysis (rate constant of NAC 
with *OH: 1.36 x lo- lo M- Is- ‘). As *OH is 
very reactive, direct antioxidant function of 
thiols may still be of great therapeutic benefit. 
Concomitantly with these in vitro results, NAC 
and NAL have inhibitory effects on H,O, pro- 
duction of cultured PMN from smokers (with 
COPD). Surprisingly, the anti-H,O, capacity of 
NAC and NAL in cultured PMN was even 
slightly higher than equimolar amounts of 
GSH. However, the rationale of this obser- 
vation remains unclear. A good anti-H,O, effect 
ex vivo may be related to both direct antioxidant 
capabilities and the cellular GSH precursor 
function. 
Furthermore, these data demonstrate that 
NAL and NAC stimulate cellular GSH produc- 
tion and GSH release into the extracellular 
milieu. Surprisingly, NAL resulted in an almost 
two-fold higher induction of intracellular GSH 
synthesis than NAC, whereas NAC stimulated 
extracellular GSH secretion more effectively. 
This result seems surprising because both thiols 
were applied in equimolar amounts. The only 
difference between the two substances is the 
L-lysine within the NAL molecule, which is 
attached via an ionic bond to the acetylcysteine 
residue (Fig. 1). As the bond is weak, lysine 
detaches readily from the NAL molecule, which 
may add to the cellular lysine content. As lysine- 
selective reagents are known to inhibit GSH 
transferase, which regulates transcellular glu- 
tathione transfer, it seems reasonable that NAL 
may indirectly induce higher intracellular GSH 
by limiting extracellular GSH secretion (43). 
Interestingly, L-lysine has an additional import- 
ant feature; dissolved L-lysine is basic, and thus, 
it can serve as a neutralizing agent in acidic 
solutions (e.g. caused by NAC) (44). Therefore, 
lysine content of NAL serves two advantages; 
it promotes intracellular GSH content, and it 
prevents acidic reaction of NAC. 
The cellular GSH effect of NAL (or NAC), 
however, is less effective than that of cystine, a 
well-known cellular precursor (45). This differ- 
ence can be sufficiently explained by the 
deacetylating of NAC to cysteine and activation 
process of cellular y-glutamyl-cycle (18,46,47). 
As the GSH precursor effect can be best demon- 
strated in cysscys-deficient cells, the authors 
cultured the A549 cells 24 h in cystine and 
cysteine-free cell medium before use. In contrast, 
the GSH precursor effect of NAC in cells cul- 
tured in non-deficient medium was just marginal 
(data not shown). In accordance with the obser- 
vation, NAC administration does not enhance 
GSH levels in patients lacking GSH deficiency 
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(e.g. COPD, normal volunteers), whereas NAC 
was effective in GSH-deficient conditions 
(4,18,39). 
In summary, this study demonstrates that 
both NAC and NAL have direct antioxidant 
capabilities. Both drugs are also able to reduce 
H,O,, which was produced by cultured granulo- 
cytes. As NAL has a greater intracellular GSH 
function than NAC in vitro, and due to the 
almost neutral pH in solution, NAL seems to be 
an interesting alternative in antioxidant therapy. 
These features of NAL make it suitable to 
augment the antioxidant screen of the lung by 
direct aerosolization. 
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